Smith+Nephew helps personalize robotically-enabled surgery with AI-powered planning software and data visualization platform

May 16, 2023 |

6 min read

Smith+Nephew, the global medical technology company, introduces two key products that close the feedback loop for its robotics and digital surgery portfolio – Personalized Planning powered by AI and RI.INSIGHTS Data Visualization Platform.

LONDON, May 16, 2023 /PRNewswire/ -- Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today introduces two key products that close the feedback loop for its robotics and digital surgery portfolio – Personalized Planning powered by AI and RI.INSIGHTS Data Visualization Platform.

These solutions transform data into contextual intelligence by enabling surgeons to see how pre-operative surgical plans and intra-operative decision-making link to post-operative outcomes.

RI.KNEE ROBOTICS™ v2.0 – Personalized Planning powered by AI
Smith+Nephew’s CORI™ Surgical System expands its capability in knee replacement with Personalized Planning powered by AI, guided by RI.INSIGHTS data. This new addition enables the surgeon to set the initial implant placement within the total knee arthroplasty procedure based on AI-guided reference values and the surgeon’s planning preferences for specific implants and patient-specific deformities.

“Advanced analytics combined with the CORI Surgical System will offer a new dimension in joint arthroplasty. It will allow for true personalization when performing joint replacement procedures,” said Dr. Thorsten Seyler of Duke University.

This AI-powered enhancement enables surgeons to customize planning to both their preferences and the patient’s anatomy at the time of surgery.

RI.INSIGHTS Data Visualization Platform
Through the RI.INSIGHTS Data Visualization Platform, surgeons can reference individual case performance and benchmark that data against an anonymised global database. The platform was designed to give surgeons a simple and effective way to link patient reported outcome measures (PROMs) to pre-operative planning and intra-operative decisions in robotically-enabled knee replacements.

Surgeon-specific dashboards provide the ability to analyze procedure data, such as case times, resections and alignment, and ligament tensioning data from the CORI Digital Tensioner. RI.INSIGHTS delivers an elegant solution to visualize data, connect PROMs, address known challenges with information access and utilization, and transform surgical insights into actionable information.

“The ability to retrospectively and prospectively evaluate and characterize data, to do what is best for every patient is unique and something we have not been able to do before now,” said Dr. Steven Nishiyama at Desert Orthopaedic Center.

Smith+Nephew’s robotics and digital surgery portfolio closes the feedback loop between intra-operative decision-making and post-operative evaluations as part of an on-going AI-initiative and continued investment in software and data solutions.

To learn more about the latest advancements in orthopaedic reconstruction and discover more about robotics and computer-guided solutions, please go to www.smith-nephew.com.

About Smith+Nephew
Smith+Nephew is a portfolio medical technology company focused on the repair, regeneration and replacement of soft and hard tissue. We exist to restore people’s bodies and their self-belief by using technology to take the limits off living. We call this purpose ‘Life Unlimited’. Our 19,000 employees deliver this mission every day, making a difference to patients’ lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global franchises of Orthopaedics, Sports Medicine & ENT and Advanced Wound Management.

Founded in Hull, UK, in 1856, we now operate in more than 100 countries, and generated annual sales of $5.2 billion in 2022. Smith+Nephew is a constituent of the FTSE100 (LSE:SN, NYSE:SNN). The terms ‘Group’ and ‘Smith+Nephew’ are used to refer to Smith & Nephew plc and its consolidated subsidiaries, unless the context requires otherwise.

For more information about Smith+Nephew, please visit www.smith-nephew.com and follow us on Twitter, LinkedIn, Instagram or Facebook.

Forward-looking Statements
This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements. Phrases such as “aim”, “plan”, “intend”, “anticipate”, “well-placed”, “believe”, “estimate”, “expect”, “target”, “consider” and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith+Nephew, these factors include: risks related to the impact of Covid, such as the depth and longevity of its impact, government actions and other restrictive measures taken in response, material delays and cancellations of elective procedures, reduced procedure capacity at medical facilities, restricted access for sales representatives to medical facilities, or our ability to execute business continuity plans as a result of Covid; economic and financial conditions in the markets we serve, especially those affecting healthcare providers, payers and customers (including, without limitation, as a result of Covid); price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal and financial compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers (including, without limitation, as a result of Covid); competition for qualified personnel; strategic actions, including acquisitions and dispositions, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; relationships with healthcare professionals; reliance on information technology and cybersecurity; disruptions due to natural disasters, weather and climate change related events; changes in customer and other stakeholder sustainability expectations; changes in taxation regulations; effects of foreign exchange volatility; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith+Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith+Nephew’s most recent annual report on Form 20-F, which is available on the SEC’s website at www. sec.gov, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith+Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith+Nephew are qualified by this caution. Smith+Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith+Nephew’s expectations.

™ Trademark of Smith+Nephew. Certain marks registered in US Patent and Trademark Office.